

PTO/SB/21 (08-04)

TRANSMITTAL FORM <small>(to be used for all correspondence after initial filing)</small>	Application Number	10/815,353	RECEIVED CENTRAL FAX CENTER MAY 06 2005
	Filing Date	March 31, 2004	
	First Named Inventor	Dale B. Schenk	
	Art Unit	1848	
	Examiner Name	Scheiner, L.	
	Attorney Docket Number	15270J-004733US	
Total Number of Pages in This Submission	30		

ENCLOSURES (Check all that apply)				
<input checked="" type="checkbox"/> Fee Transmittal Form (1 p., submitted in duplicate) <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input checked="" type="checkbox"/> Terminal Disclaimers over 6,787,523, 6,787,143, 6,787,138, 6,787,144, 6,787,139, 6,787,140, 6,866,850, 6,818,218 and 6,866,849 <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):		
<table border="1" style="width: 100%;"> <tr> <td style="width: 15%;">Remarks</td> <td> The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430. The attached Terminal Disclaimers, which disclaim U.S. Application No. 09/201,430, issued as U.S. Patent No. 6,787,523, 09/724,477, issued as U.S. Patent No. 6,787,143, 09/723,927, issued as U.S. Patent No. 6,787,138, 09/723,762, issued as U.S. Patent No. 6,787,144, 09/724,102, issued as U.S. Patent No. 6,787,139, 09/724,489, issued as U.S. Patent No. 6,787,140, 10/816,022, issued as U.S. Patent No. 6,866,850, 10/816,529, issued as U.S. Patent No. 6,818,218, and 10/815,391, issued as U.S. Patent No. 6,866,849, are being filed simply as a precaution and should not be construed as an acquiescence to obviousness type double patenting. </td> </tr> </table>			Remarks	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430. The attached Terminal Disclaimers, which disclaim U.S. Application No. 09/201,430, issued as U.S. Patent No. 6,787,523, 09/724,477, issued as U.S. Patent No. 6,787,143, 09/723,927, issued as U.S. Patent No. 6,787,138, 09/723,762, issued as U.S. Patent No. 6,787,144, 09/724,102, issued as U.S. Patent No. 6,787,139, 09/724,489, issued as U.S. Patent No. 6,787,140, 10/816,022, issued as U.S. Patent No. 6,866,850, 10/816,529, issued as U.S. Patent No. 6,818,218, and 10/815,391, issued as U.S. Patent No. 6,866,849, are being filed simply as a precaution and should not be construed as an acquiescence to obviousness type double patenting.
Remarks	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430. The attached Terminal Disclaimers, which disclaim U.S. Application No. 09/201,430, issued as U.S. Patent No. 6,787,523, 09/724,477, issued as U.S. Patent No. 6,787,143, 09/723,927, issued as U.S. Patent No. 6,787,138, 09/723,762, issued as U.S. Patent No. 6,787,144, 09/724,102, issued as U.S. Patent No. 6,787,139, 09/724,489, issued as U.S. Patent No. 6,787,140, 10/816,022, issued as U.S. Patent No. 6,866,850, 10/816,529, issued as U.S. Patent No. 6,818,218, and 10/815,391, issued as U.S. Patent No. 6,866,849, are being filed simply as a precaution and should not be construed as an acquiescence to obviousness type double patenting.			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT				
Firm Name	Townsend and Townsend and Crew LLP			
Signature	<i>Rosemarie L. Celli</i>			
Printed name	Rosemarie L. Celli			
Date	<i>May 6, 2005</i>	Reg. No. 42,397		

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, Fax No. (703) 872-8308 on <i>5/6/05</i> .			
Signature	<i>Hubert Baker</i>		
Typed or printed name	Hubert Baker	Date	<i>5/6/05</i>

PTO/BB/17 (12-04)

Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4318). <h1 style="text-align: center;">FEE TRANSMITTAL</h1> <h2 style="text-align: center;">For FY 2005</h2>		Complete If Known	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Application Number	10/815,353
		Filing Date	March 31, 2004
		First Named Inventor	Dale B. Schenk
		Examiner Name	Schelnor, L.
		Art Unit	1848
TOTAL AMOUNT OF PAYMENT (\$) 1170		Attorney Docket No.	15270J-004733US

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____
☒ Deposit Account Deposit Account Number: 20-1430 Deposit Account Name: Townsend and Townsend and Crew LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee
☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-3038

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Small Entity	
	Fee (\$)	Fee (\$)
Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent	50	25
Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent	200	100
Multiple dependent claims	360	180

Total Claims _____ Extra Claims _____ Fee (\$) _____ Fee Paid (\$) _____
 -20 or HP = _____ x _____ = _____
 HP = highest number of total claims paid for, if greater than 20
 Indep. Claims _____ Extra Claims _____ Fee (\$) _____ Fee Paid (\$) _____
 -3 or HP = _____ x _____ = _____
 HP = highest number of independent claims paid for, if greater than 3

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(e).

Total Sheets _____ Extra Sheets _____ Number of each additional 50 or fraction thereof _____ Fee (\$) _____ Fee Paid (\$) _____
 - 100 = _____ / 50 = _____ (round up to a whole number) x _____ = _____

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other: 1.20(d) Statutory (Terminal) Disclaimer Fee 9@130

Fees Paid (\$)

1170

SUBMITTED BY		
Signature	<i>Rosemarie L. Celli</i>	Registration No. (Attorney/Agent) 42,397
Name (Print/Type)	Rosemarie L. Celli	Telephone 650-326-2400
		Date <i>May 6, 2005</i>

60485773 v1

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-703-872-9306 on

May 6, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: 

PATENT
Attorney Docket No.: 15270J-4733US

RECEIVED
CENTRAL FAX CENTER

MAY 06 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,353

Filed: March 31, 2004

Patent No.: 6,808,712

Issue Date: October 26, 2004

For: PREVENTION AND TREATMENT OF
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

1. Application No. 10/815,353 Issued as U.S. Patent No. 6,808,712 (the "712 PATENT")
2. Application No. 09/201,430 Issued as U.S. Patent No. 6,787,523 (the "523 PATENT")

SCHENK, Dale B.
Application No.: 10/815,353
Page 2

PATENT

ASSIGNEE is the exclusive owner of the '712 PATENT and the '523 PATENT.

ASSIGNEE disclaims the terminal part of any patent granted on the '712 PATENT which would extend beyond the last day of the full statutory term of the '523 PATENT.

Further, ASSIGNEE agrees that any patent granted on the '712 PATENT shall be enforceable only for and during the period that the legal title to the patent granted on the '712 PATENT shall be the same as the legal title to the '523 PATENT and agrees that this Terminal Disclaimer shall run with any patent granted on the '712 PATENT and shall be binding on the grantee or its successors or assigns.

In making the above disclaimer, ASSIGNEE does not disclaim the terminal part of any patent granted on the '712 PATENT that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the '523 PATENT, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

This disclaimer is directed to patents issuing from the indicated '712 PATENT only and is not intended to act as a disclaimer of any part of the statutory term of any patent issuing from a divisional or continuation application that claims priority to either the '712 PATENT or to use the term of such a patent issuing from a divisional or continuation application in calculating the term of the present '712 PATENT.

The assignment documents evidencing title referred to above have been reviewed by the undersigned, and it is certified that title is in the ASSIGNEE.


SCHENK, Dale B.
Application No.: 10/815,353
Page 3

PATENT

DECLARATION

The undersigned declares further that all statements made herein of her own knowledge are true and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

Respectfully submitted,


Rosemarie L. Celli
Reg. No. 42,397


TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400/Fax: (650) 326-2422
RLC:aeb
60485899 v1

I hereby certify that this correspondence is being facsimile
transmitted to the U.S. Patent and Trademark Office, Fax
No. 1-703-872-9306 on

PATENT
Attorney Docket No.: 15270J-4733US

May 6, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: 

RECEIVED
CENTRAL FAX CENTER

MAY 06 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,353

Filed: March 31, 2004

Patent No.: 6,808,712

Issue Date: October 26, 2004

For: PREVENTION AND TREATMENT OF
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter
"ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is
the assignee of total interest of:

1. Application No. 10/815,353 Issued as U.S. Patent No. 6,808,712 (the "712 PATENT")
2. Application No. 09/724,477 Issued as U.S. Patent No. 6,787,143 (the "143 PATENT")

SCHENK, Dale B.
Application No.: 10/815,353
Page 2

PATENT

ASSIGNEE is the exclusive owner of the '712 PATENT and the '143 PATENT.
ASSIGNEE disclaims the terminal part of any patent granted on the '712 PATENT which would extend beyond the last day of the full statutory term of the '143 PATENT.

Further, ASSIGNEE agrees that any patent granted on the '712 PATENT shall be enforceable only for and during the period that the legal title to the patent granted on the '712 PATENT shall be the same as the legal title to the '143 PATENT and agrees that this Terminal Disclaimer shall run with any patent granted on the '712 PATENT and shall be binding on the grantee or its successors or assigns.

In making the above disclaimer, ASSIGNEE does not disclaim the terminal part of any patent granted on the '712 PATENT that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the '143 PATENT, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

This disclaimer is directed to patents issuing from the indicated '712 PATENT only and is not intended to act as a disclaimer of any part of the statutory term of any patent issuing from a divisional or continuation application that claims priority to either the '712 PATENT or to use the term of such a patent issuing from a divisional or continuation application in calculating the term of the present '712 PATENT.

The assignment documents evidencing title referred to above have been reviewed by the undersigned, and it is certified that title is in the ASSIGNEE.


SCHENK, Dale B.
Application No.: 10/815,353
Page 3

PATENT

DECLARATION

The undersigned declares further that all statements made herein of her own knowledge are true and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400/Fax: (650) 326-2422
RLC:aeb
60485706 v1

I heroby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-703-872-9306 on

May 6, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: 

PATENT
Attorney Docket No.: 15270J-4733US

RECEIVED
CENTRAL FAX CENTER

MAY 06 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,353

Filed: March 31, 2004

Patent No.: 6,808,712

Issue Date: October 26, 2004

For: PREVENTION AND TREATMENT OF
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

1. Application No. 10/815,353 Issued as U.S. Patent No. 6,808,712 (the "712 PATENT")
2. Application No. 09/723,927 Issued as U.S. Patent No. 6,787,138 (the "138 PATENT")

SCHENK, Dale B.
Application No.: 10/815,353
Page 2

PATENT

ASSIGNEE is the exclusive owner of the '712 PATENT and the '138 PATENT.
ASSIGNEE disclaims the terminal part of any patent granted on the '712 PATENT which would extend beyond the last day of the full statutory term of the '138 PATENT.

Further, ASSIGNEE agrees that any patent granted on the '712 PATENT shall be enforceable only for and during the period that the legal title to the patent granted on the '712 PATENT shall be the same as the legal title to the '138 PATENT and agrees that this Terminal Disclaimer shall run with any patent granted on the '712 PATENT and shall be binding on the grantee or its successors or assigns.

In making the above disclaimer, ASSIGNEE does not disclaim the terminal part of any patent granted on the '712 PATENT that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the '138 PATENT, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

This disclaimer is directed to patents issuing from the indicated '712 PATENT only and is not intended to act as a disclaimer of any part of the statutory term of any patent issuing from a divisional or continuation application that claims priority to either the '712 PATENT or to use the term of such a patent issuing from a divisional or continuation application in calculating the term of the present '712 PATENT.

The assignment documents evidencing title referred to above have been reviewed by the undersigned, and it is certified that title is in the ASSIGNEE.


SCHENK, Dale B.
Application No.: 10/815,353
Page 3

PATENT

DECLARATION

The undersigned declares further that all statements made herein of her own knowledge are true and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

Respectfully submitted,


Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400/Fax: (650) 326-2422
RLC:aeb
60485710 v1

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-703-872-9306 on

PATENT
Attorney Docket No.: 15270J-4733US

May 6, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: Robert Ben

RECEIVED
CENTRAL FAX CENTER

MAY 06 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,353

Filed: March 31, 2004

Patent No.: 6,808,712

Issue Date: October 26, 2004

For: PREVENTION AND TREATMENT OF
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNER") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

1. Application No. 10/815,353 Issued as U.S. Patent No. 6,808,712 (the "712 PATENT")
2. Application No. 09/723,762 Issued as U.S. Patent No. 6,787,144 (the "144 PATENT")

SCHENK, Dale B.
Application No.: 10/815,353
Page 2

PATENT

ASSIGNEE is the exclusive owner of the '712 PATENT and the '144 PATENT.
ASSIGNEE disclaims the terminal part of any patent granted on the '712 PATENT which would extend beyond the last day of the full statutory term of the '144 PATENT.

Further, ASSIGNEE agrees that any patent granted on the '712 PATENT shall be enforceable only for and during the period that the legal title to the patent granted on the '712 PATENT shall be the same as the legal title to the '144 PATENT and agrees that this Terminal Disclaimer shall run with any patent granted on the '712 PATENT and shall be binding on the grantee or its successors or assigns.

In making the above disclaimer, ASSIGNEE does not disclaim the terminal part of any patent granted on the '712 PATENT that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the '144 PATENT, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

This disclaimer is directed to patents issuing from the indicated '712 PATENT only and is not intended to act as a disclaimer of any part of the statutory term of any patent issuing from a divisional or continuation application that claims priority to either the '712 PATENT or to use the term of such a patent issuing from a divisional or continuation application in calculating the term of the present '712 PATENT.

The assignment documents evidencing title referred to above have been reviewed by the undersigned, and it is certified that title is in the ASSIGNEE.

SCHENK, Dale B.
Application No.: 10/815,353
Page 3

PATENT

DECLARATION

The undersigned declares further that all statements made herein of her own knowledge are true and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400/Fax: (650) 326-2422
RLC:aeb
60485735 v1

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-703-872-9306 on

PATENT
Attorney Docket No.: 15270J-4733US

May 6, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: Robert Bar

RECEIVED
CENTRAL FAX CENTER

MAY 06 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,353

Filed: March 31, 2004

Patent No.: 6,808,712

Issue Date: October 26, 2004

For: PREVENTION AND TREATMENT OF
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

1. Application No. 10/815,353 Issued as U.S. Patent No. 6,808,712 (the "712 PATENT")
2. Application No. 09/724,102 Issued as U.S. Patent No. 6,787,139 (the "139 PATENT")

SCHENK, Dale B.
Application No.: 10/815,353
Page 2

PATENT

ASSIGNEE is the exclusive owner of the '712 PATENT and the '139 PATENT.
ASSIGNEE disclaims the terminal part of any patent granted on the '712 PATENT which would extend beyond the last day of the full statutory term of the '139 PATENT.

Further, ASSIGNEE agrees that any patent granted on the '712 PATENT shall be enforceable only for and during the period that the legal title to the patent granted on the '712 PATENT shall be the same as the legal title to the '139 PATENT and agrees that this Terminal Disclaimer shall run with any patent granted on the '712 PATENT and shall be binding on the grantee or its successors or assigns.

In making the above disclaimer, ASSIGNEE does not disclaim the terminal part of any patent granted on the '712 PATENT that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the '139 PATENT, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

This disclaimer is directed to patents issuing from the indicated '712 PATENT only and is not intended to act as a disclaimer of any part of the statutory term of any patent issuing from a divisional or continuation application that claims priority to either the '712 PATENT or to use the term of such a patent issuing from a divisional or continuation application in calculating the term of the present '712 PATENT.

The assignment documents evidencing title referred to above have been reviewed by the undersigned, and it is certified that title is in the ASSIGNEE.


SCHENK, Dale B.
Application No.: 10/815,353
Page 3

PATENT

DECLARATION

The undersigned declares further that all statements made herein of her own knowledge are true and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397


TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400/Fax: (650) 326-2422
RLC:aeb
60485748 v1

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-703-872-9306 on

PATENT
Attorney Docket No.: 15270J-4733US

May 6, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: 

RECEIVED
CENTRAL FAX CENTER

MAY 06 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,353

Filed: March 31, 2004

Patent No.: 6,808,712

Issue Date: October 26, 2004

For: PREVENTION AND TREATMENT OF
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

1. Application No. 10/815,353 Issued as U.S. Patent No. 6,808,712 (the "712 PATENT")
2. Application No. 09/724,489 Issued as U.S. Patent No. 6,787,140 (the "140 PATENT")

SCHENK, Dale B.
Application No.: 10/815,353
Page 2

PATENT

ASSIGNEE is the exclusive owner of the '712 PATENT and the '140 PATENT.
ASSIGNEE disclaims the terminal part of any patent granted on the '712 PATENT which would extend beyond the last day of the full statutory term of the '140 PATENT.

Further, ASSIGNEE agrees that any patent granted on the '712 PATENT shall be enforceable only for and during the period that the legal title to the patent granted on the '712 PATENT shall be the same as the legal title to the '140 PATENT and agrees that this Terminal Disclaimer shall run with any patent granted on the '712 PATENT and shall be binding on the grantee or its successors or assigns.

In making the above disclaimer, ASSIGNEE does not disclaim the terminal part of any patent granted on the '712 PATENT that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the '140 PATENT, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

This disclaimer is directed to patents issuing from the indicated '712 PATENT only and is not intended to act as a disclaimer of any part of the statutory term of any patent issuing from a divisional or continuation application that claims priority to either the '712 PATENT or to use the term of such a patent issuing from a divisional or continuation application in calculating the term of the present '712 PATENT.

The assignment documents evidencing title referred to above have been reviewed by the undersigned, and it is certified that title is in the ASSIGNEE.


SCHENK, Dale B.
Application No.: 10/815,353
Page 3

PATENT

DECLARATION

The undersigned declares further that all statements made herein of her own knowledge are true and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

Respectfully submitted,


Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400/Fax: (650) 326-2422
RLC:aeb
60485751 v1

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-703-872-9306 on

May 6, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: Anthony B.

PATENT
Attorney Docket No.: 15270J-4733US

RECEIVED
CENTRAL FAX CENTER

MAY 06 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,353

Filed: March 31, 2004

Patent No.: 6,808,712

Issue Date: October 26, 2004

For: PREVENTION AND TREATMENT OF
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

1. Application No. 10/815,353 Issued as U.S. Patent No. 6,808,712 (the "712 PATENT")
2. Application No. 10/816,022 Issued as U.S. Patent No. 6,866,850 (the "850 PATENT")

SCHENK, Dale B.
Application No.: 10/815,353
Page 2

PATENT

ASSIGNEE is the exclusive owner of the '712 PATENT and the '850 PATENT.
ASSIGNEE disclaims the terminal part of any patent granted on the '712 PATENT which would extend beyond the last day of the full statutory term of the '850 PATENT.

Further, ASSIGNEE agrees that any patent granted on the '712 PATENT shall be enforceable only for and during the period that the legal title to the patent granted on the '712 PATENT shall be the same as the legal title to the '850 PATENT and agrees that this Terminal Disclaimer shall run with any patent granted on the '712 PATENT and shall be binding on the grantee or its successors or assigns.

In making the above disclaimer, ASSIGNEE does not disclaim the terminal part of any patent granted on the '712 PATENT that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the '850 PATENT, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

This disclaimer is directed to patents issuing from the indicated '712 PATENT only and is not intended to act as a disclaimer of any part of the statutory term of any patent issuing from a divisional or continuation application that claims priority to either the '712 PATENT or to use the term of such a patent issuing from a divisional or continuation application in calculating the term of the present '712 PATENT.

The assignment documents evidencing title referred to above have been reviewed by the undersigned, and it is certified that title is in the ASSIGNEE.


SCHENK, Dale B.
Application No.: 10/815,353
Page 3

PATENT

DECLARATION

The undersigned declares further that all statements made herein of her own knowledge are true and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

Respectfully submitted,


Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400/Fax: (650) 326-2422
RLC:asb
60485756 v1

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-703-872-9306 on

May 6, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: Anthony Bar

PATENT
Attorney Docket No.: 15270J-4733US

RECEIVED
CENTRAL FAX CENTER

MAY -0 6 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,353

Filed: March 31, 2004

Patent No.: 6,808,712

Issue Date: October 26, 2004

For: PREVENTION AND TREATMENT OF
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

1. Application No. 10/815,353 Issued as U.S. Patent No. 6,808,712 (the "712 PATENT")
2. Application No. 10/816,529 Issued as U.S. Patent No. 6,818,218 (the "218 PATENT")

SCHENK, Dale B.
Application No.: 10/815,353
Page 2

PATENT

ASSIGNEE is the exclusive owner of the '712 PATENT and the '218 PATENT.
ASSIGNEE disclaims the terminal part of any patent granted on the '712 PATENT which would extend beyond the last day of the full statutory term of the '218 PATENT.

Further, ASSIGNEE agrees that any patent granted on the '712 PATENT shall be enforceable only for and during the period that the legal title to the patent granted on the '712 PATENT shall be the same as the legal title to the '218 PATENT and agrees that this Terminal Disclaimer shall run with any patent granted on the '712 PATENT and shall be binding on the grantee or its successors or assigns.

In making the above disclaimer, ASSIGNEE does not disclaim the terminal part of any patent granted on the '712 PATENT that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the '218 PATENT, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

This disclaimer is directed to patents issuing from the indicated '712 PATENT only and is not intended to act as a disclaimer of any part of the statutory term of any patent issuing from a divisional or continuation application that claims priority to either the '712 PATENT or to use the term of such a patent issuing from a divisional or continuation application in calculating the term of the present '712 PATENT.

The assignment documents evidencing title referred to above have been reviewed by the undersigned, and it is certified that title is in the ASSIGNEE.


SCHENK, Dale B.
Application No.: 10/815,353
Page 3

PATENT

DECLARATION

The undersigned declares further that all statements made herein of her own knowledge are true and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400/Fax: (650) 326-2422
RLC:aeb
60485758 v1

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-703-872-9306 on

May 6, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: Robert Bar

PATENT
Attorney Docket No.: 15270J-4733US

RECEIVED
CENTRAL FAX CENTER

MAY 06 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,353

Filed: March 31, 2004

Patent No.: 6,808,712

Issue Date: October 26, 2004

For: PREVENTION AND TREATMENT OF
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

1. Application No. 10/815,353 Issued as U.S. Patent No. 6,808,712 (the "712 PATENT")
2. Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "849 PATENT")

SCHENK, Dale B.
Application No.: 10/815,353
Page 2

PATENT

ASSIGNEE is the exclusive owner of the '712 PATENT and the '849 PATENT.
ASSIGNEE disclaims the terminal part of any patent granted on the '712 PATENT which would extend beyond the last day of the full statutory term of the '849 PATENT.

Further, ASSIGNEE agrees that any patent granted on the '712 PATENT shall be enforceable only for and during the period that the legal title to the patent granted on the '712 PATENT shall be the same as the legal title to the '849 PATENT and agrees that this Terminal Disclaimer shall run with any patent granted on the '712 PATENT and shall be binding on the grantee or its successors or assigns.

In making the above disclaimer, ASSIGNEE does not disclaim the terminal part of any patent granted on the '712 PATENT that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the '849 PATENT, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

This disclaimer is directed to patents issuing from the indicated '712 PATENT only and is not intended to act as a disclaimer of any part of the statutory term of any patent issuing from a divisional or continuation application that claims priority to either the '712 PATENT or to use the term of such a patent issuing from a divisional or continuation application in calculating the term of the present '712 PATENT.

The assignment documents evidencing title referred to above have been reviewed by the undersigned, and it is certified that title is in the ASSIGNEE.


SCHENK, Dale B.
Application No.: 10/815,353
Page 3

PATENT

DECLARATION

The undersigned declares further that all statements made herein of her own knowledge are true and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400/Fax: (650) 326-2422
RLC:aeb
60485765 v1